The firm
Tina Khadivi and Troy Assoignon bring complementary perspectives to the same question: where can a clearer strategy create more value?
Healthcare & investment perspective
Partner and CFO/COO at Surevix. Its July 2026 deck credits Tina with raising $150M+ for public and private companies and advising 30+ founders.
A two-time founder across fintech and seniors wellness, and venture partner with Ace Ventures. Her deck describes experience spanning $30M ventures to $800M Nasdaq-listed companies, with advisory relationships across healthcare innovation.
Professional profile ↗
Positioning & revenue recovery
Strategist connecting positioning, demand generation and execution. His published work spans software growth, fund narratives and substantial advertising investment.
Focuses on the commercial opportunities inside the offer, message, pipeline, follow-up and systems that support growth.
Professional profile ↗The partners / selected individual experience
Surevix’s July 2026 overview attributes $150M+ in fundraising to Tina, with experience spanning $30M ventures to $800M Nasdaq-listed companies.
The deck describes founder advisory across dental technology, medical devices, genomics, radiology and biopharma.
Troy’s published case summary associates software growth strategy with $7.6M in client profit.
Designed assets supporting a real estate fund raise completed over six months.
Troy’s public biography reports personal management of millions in advertising spend.
Published fundraising result associated with an initiative supporting 2,750 evacuations.
Prior individual experience: Tina’s figures from the supplied Surevix deck; Troy’s from his published materials. Not aggregated JV performance. Source details below.
Tina’s advisory & investment background
Devices & care delivery
The Surevix deck lists advisory references associated with dental-lab technology and medical-device innovation.
Healthcare AI
Named advisory references in genomics and AI-enabled radiology.
Biopharma
Named advisory references in neurological and clinical-stage biopharma.
Source: Surevix overview, July 2026, p. 3. The deck also identifies Tina as an early investor in Blossom Social and a venture partner at Ace Ventures. These are individual relationships, not JV clients or endorsements.
A focused advisory relationship
Direct involvement
The engagement is shaped around leadership’s priorities, with partner involvement in diagnosis, strategy and key decisions.
Focused execution
Agree the work, decision-makers and specialists required. Align existing teams and agencies around the commercial objective.
Useful measurement
Establish a baseline, assign owners and track outcomes appropriate to the business and the available data.
Primary sectors: healthcare and mining, across public and private ownership. Select adjacent mandates considered for REITs, Series A businesses and investment portfolios.
Experience & research
Tina’s credentials and advisory references come from the supplied Surevix Firm Overview Deck, July 2026, particularly page 3. The deck identifies her as Partner / CFO / COO, attributes $150M+ raised and 30+ founders advised to her, and provides the named advisory references. These are source-reported credentials, not independently audited results. Surevix and Ace Ventures are separate organizations, not asserted sponsors of this JV.
Troy’s financial outcomes are self-published at Positioning Expert. Advertising experience is described in his public biography. The figures measure different activities and are not added together. Currency is presented as reported by the original sources.
The deck separately attributes the specialty pharmacy’s $300M+ annualized revenue, 46-state licensure and 98% retention to operating principal Dominick Spada’s history. Ace Ventures’ 140 investments and 32 exits belong to that firm. The anonymous capital partners’ platform sizes and acquisition records belong to those partners. None is represented as a JV result, committed JV funding or a confirmed member of the JV delivery team.
Download the complete deck proof register for all claims, page references and attribution.
The mandate design draws on Notified’s discussion with global investor-relations associations, IQVIA’s healthcare marketing and operations perspective, and EY’s 2026 mining and metals research. These inform the proposed approach; they are not partner case studies.
Download the research briefA conversation with the partners
Discuss your commercial priorities, current investment and the opportunity ahead.